Kura Oncology insider files Form 144 for 12,314-share PSU sale
Rhea-AI Filing Summary
Kura Oncology Form 144 notice reporting a proposed sale of 12,314 shares of common stock. The filer intends to sell the shares through Morgan Stanley Smith Barney LLC on NASDAQ around 09/29/2025, with an aggregate market value listed at $111,441.70. The shares were acquired two days earlier on 09/27/2025 as performance stock units (PSUs) issued by the company and are to be paid/settled on 09/29/2025. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sale of recently issued PSUs, small relative to outstanding shares; appears procedural rather than market-moving.
The notice documents a proposed sale of 12,314 common shares acquired as performance stock units two days prior to the intended sale. At an aggregate value of $111,441.70 against 87,015,518 shares outstanding, the transaction represents a de minimis portion of the capital base. The timing—immediate post-issuance settlement—and the seller's attestation of no undisclosed material information suggest a routine disposition of vested compensation rather than a sale prompted by company-specific adverse developments. No other recent sales by the same person are reported.
TL;DR: Filing documents compliant Rule 144 sale of PSUs; disclosure is standard and contains required attestations.
The Form 144 provides required broker, share count, acquisition method (PSU), and settlement timing. The broker identified is Morgan Stanley Smith Barney LLC and the planned execution venue is NASDAQ. The signer makes the statutory representation about lack of undisclosed material information and the form indicates no aggregated prior sales. From a governance and compliance perspective, the filing meets procedural requirements for public disclosure of an insider sale tied to compensation vesting.